eMedicine Specialties > Ophthalmology > Dermatologic Disorders

Dermatitis, Contact: Treatment & Medication

Author: R Scott Lowery, MD, Assistant Professor of Ophthalmology, Department of Pediatric Ophthalmology and Strabismus, University of Arkansas for Medical Center, Arkansas Children's Hospital
Contributor Information and Disclosures

Updated: Oct 30, 2009

Treatment

Medical Care

The medical care for contact dermatitis simply involves removal of the offending agent from the patient's environment (if it can be identified). This may be impossible because of a patient's work environment or economic situation.7

Clothing to limit exposure may be useful. Harsh soaps and detergents should be avoided. Sweating and cold weather may cause exacerbations. Irritating fabrics and scratching also are problematic. Typical treatment involves topical steroids to the affected area and wet saline compresses to exudative skin lesions. Oral antihistamines may be used for control of itching. Oral steroids may be used if control with topical treatment is not sufficient.

Consultations

Dermatologic consultation may be helpful if skin involvement is severe or if patch testing is necessary.

Diet

Food allergens do not commonly cause contact dermatitis, although this may occur. If the offending agent is believed to be in a particular food, atopic dermatitis and urticaria should be considered as possible diagnoses.

Medication

Contact dermatitis is treated by identifying and removing the offending agent (if possible) and treating conservatively based upon the degree of symptoms. Frequently, removing the agent and allowing a short time for the symptoms to resolve will be adequate treatment. Otherwise, symptoms may be too severe and may require one or more of the following: topical corticosteroids, oral antihistamines, and oral corticosteroids.

Corticosteroids

Have anti-inflammatory properties and cause profound and varied metabolic effects. Corticosteroids modify the body's immune response to diverse stimuli. Various preparations of corticosteroids are available as eye drops that may be used for contact dermatitis affecting the eye.


Triamcinolone (Aristocort, Kenalog, Trilone)

Topical form in a water-soluble base should be sufficient to control most forms of contact dermatitis that occur on skin. Patients must be seen if symptoms do not improve within a few days.

Adult

Apply topically tid to affected area of skin

Pediatric

Not established

Documented hypersensitivity; fungal, viral, and bacterial skin infections

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Retardation of wound healing possible with prolonged treatment; may increase IOP; prolonged use may result in glaucoma


Prednisolone (Pred Forte)

Decreases inflammation and corneal neovascularization. Suppresses migration of polymorphonuclear leukocytes and reverses increased capillary permeability.

Adult

Solution: 1-2 gtt into conjunctival sac q1h during day and q2h noct; once desired response is obtained, use 1 gtt q4h; may reduce to 1 gtt tid/qid to control symptoms
Suspension: Shake well before using and instill 1-2 gtt into conjunctival sac 2-4 times/d; if necessary, may increase dosing frequency during initial 24-48 h

Pediatric

Administer as in adults

Documented hypersensitivity; most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also mycobacterial infections of the eye and fungal diseases of ocular structures

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in hypertension; known to cause cataract formation with long-term use; may cause secondary glaucoma; suspect fungal invasion in any persistent corneal ulceration where a corticosteroid has been used or is in use (obtain fungal cultures when appropriate); may increase IOP; prolonged use may result in glaucoma


Prednisone (Deltasone, Meticorten, Orasone, Sterapred)

Oral form may be necessary if skin lesions are widespread and do not respond initially to topical steroids. A high dose may be given initially with a slow taper for a large affected area. Use should be limited to short periods because of the risks of long-term use, especially in children.

Adult

5-10 mg PO qd

Pediatric

Not established

Coadministration with estrogens may decrease prednisone clearance; concurrent use with digoxin may cause digitalis toxicity secondary to hypokalemia; phenobarbital, phenytoin, and rifampin may increase metabolism of glucocorticoids (consider increasing maintenance dose); monitor for hypokalemia with coadministration of diuretics

Documented hypersensitivity; viral infection; peptic ulcer disease; hepatic dysfunction; connective tissue infections; fungal or tubercular skin infections; GI disease

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Abrupt discontinuation of glucocorticoids may cause adrenal crisis; hyperglycemia, edema, osteonecrosis, myopathy, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, myasthenia gravis, growth suppression, and infections may occur with glucocorticoid use; may increase IOP; prolonged use may result in glaucoma

Oral antihistamines

Act by competitive inhibition of histamine at the H1 receptor. This mediates the wheal and flare reactions, bronchial constriction, mucous secretion, smooth muscle contraction, edema, hypotension, CNS depression, and cardiac arrhythmias.


Hydroxyzine (Atarax, Vistaril, Vistazine)

Antagonizes H1 receptors in periphery. May suppress histamine activity in subcortical region of CNS.

Adult

5-25 mg PO qd/qid (25 mg tid/qid per PDR)

Pediatric

<6 years: 50 mg PO qd divided into several doses
>6 years: 50-100 mg PO qd divided into several doses (according to PDR)

CNS depression may increase with alcohol or other CNS depressants

Documented hypersensitivity; early pregnancy

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Associated with clinical exacerbations of porphyria (may not be safe for porphyric patients); ECG abnormalities (alterations in T-waves) may occur; may cause drowsiness necessitating avoidance of driving, operating heavy machinery, and alcohol use

More on Dermatitis, Contact

Overview: Dermatitis, Contact
Differential Diagnoses & Workup: Dermatitis, Contact
Treatment & Medication: Dermatitis, Contact
Follow-up: Dermatitis, Contact
References
Further Reading
[ CLOSE WINDOW ]

References

  1. Rietschel RL, Fowler JF. Fisher's Contact Dermatitis. 4th ed. Lippincott Williams & Wilkins; 1995.

  2. Geraut C, Tripodi D, Brunet-Courtois B, Leray F, Geraut L. Occupational dermatitis to epoxydic and phenolic resins. Eur J Dermatol. Apr 7 2009;[Medline].

  3. Pontén A, Dubnika I. Delayed reactions to reusable protective gloves. Contact Dermatitis. Apr 2009;60(4):227-9. [Medline].

  4. Helaskoski E, Kuuliala O, Aalto-Korte K. Occupational contact urticaria caused by cyclic acid anhydrides. Contact Dermatitis. Apr 2009;60(4):214-21. [Medline].

  5. Glick ZR, Saedi N, Ehrlich A. Allergic contact dermatitis from cigarettes. Dermatitis. Jan-Feb 2009;20(1):6-13. [Medline].

  6. Tudela E, MacPherson C, Maibach HI. Long-term trend in patch test reactions: a 32-year statistical overview (1970-2002), part II. Cutan Ocul Toxicol. 2008;27(3):187-202.

  7. Bourke J, Coulson I, English J. Guidelines for the management of contact dermatitis: an update. Br J Dermatol. Mar 19 2009;[Medline].

  8. Ayala F, Fabbrocini G, Bacchilega R. Eyelid dermatitis: an evaluation of 447 patients. Am J Contact Dermat. Jun 2003;14(2):69-74. [Medline].

  9. Cohen DE. Contact dermatitis: a quarter century perspective. J Am Acad Dermatol. Jul 2004;51(1 Suppl):S60-3. [Medline].

  10. Friedlander MH. Contact dermatitis. In: Current Ocular Therapy. 5th ed. Elsevier Science; 2000:143-146.

  11. Garrott HM, Walland MJ. Glaucoma from topical corticosteroids to the eyelids. Clin Experiment Ophthalmol. Apr 2004;32(2):224-6. [Medline].

  12. Guin JD. Eyelid dermatitis: experience in 203 cases. J Am Acad Dermatol. Nov 2002;47(5):755-65. [Medline].

  13. Kanski JJ. Disorders of the conjunctiva. In: Clinical Ophthalmology: A Systematic Approach. 4th ed. Elsevier Science; 1999:69-75.

  14. Kulkarni PS, Meredith TA. Steroids in ocular therapy, antiallergic therapies. In: Zimmerman TJ, ed. Textbook of Ocular Pharmacology. Lippincott Williams & Wilkins; 1997:61-74, 363-85, 609-33, 683-701, 801-4.

  15. Kutting B, Brehler R, Traupe H. Allergic contact dermatitis in children: strategies of prevention and risk management. Eur J Dermatol. Mar-Apr 2004;14(2):80-5. [Medline].

  16. Kwan TH. Spongiotic dermatitis. In: Textbook of Dermatopathology. McGraw-Hill Co; 1998:17-32.

  17. Manni G, Centofanti M, Sacchetti M. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy. J Glaucoma. Apr 2004;13(2):163-7. [Medline].

  18. Marks JG, Martini MC. Contact dermatitis and contact urticaria. In: Principle and Practice of Dermatology. 2nd ed. Churchill Livingstone; 1996:419-427.

  19. Roy FH. Ocular Differential Diagnosis. 6th ed. Lippincott Williams & Wilkins; 2000.

  20. Weisbecker CA, Fraunfelder FT, Rhee D. Physicians' Desk Reference for Ophthalmology. 28th ed. Medical Economics Co; 2000.

[ CLOSE WINDOW ]

Keywords

contact dermatitis, contact allergy, contact sensitivity, dermatitis venenata

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

R Scott Lowery, MD, Assistant Professor of Ophthalmology, Department of Pediatric Ophthalmology and Strabismus, University of Arkansas for Medical Center, Arkansas Children's Hospital
R Scott Lowery, MD is a member of the following medical societies: American Academy of Ophthalmology
Disclosure: Nothing to disclose.

Medical Editor

Jack L Wilson, PhD, Distinguished Professor, Department of Anatomy and Neurobiology, University of Tennessee at Memphis
Jack L Wilson, PhD is a member of the following medical societies: American Association of Anatomists, American Association of Clinical Anatomists, and American Heart Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Simon K Law, MD, PharmD, Assistant Professor of Ophthalmology, Jules Stein Eye Institute; Chief of Section of Ophthalmology Surgical Services, Department of Veterans Affairs Healthcare Center, West Los Angeles
Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Association for Research in Vision and Ophthalmology
Disclosure: Nothing to disclose.

Managing Editor

Christopher J Rapuano, MD, Professor, Department of Ophthalmology, Jefferson Medical College of Thomas Jefferson University; Co-Chairman of the Cornea Service, Co-Chairman of Refractive Surgery Department, Wills Eye Institute
Christopher J Rapuano, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, Contact Lens Association of Ophthalmologists, Cornea Society, Eye Bank Association of America, International Society of Refractive Surgery, and Pan-American Association of Ophthalmology
Disclosure: Allergan Honoraria Speaking and teaching; Allergan Consulting fee Consulting; Alcon Honoraria Speaking and teaching; Inspire Honoraria Speaking and teaching; RPS Ownership interest Other; Vistakon Honoraria Speaking and teaching

CME Editor

Lance L Brown, OD, MD, Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri
Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences
Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.